erlotinib hydrochloride has been researched along with 6 beta-hydroxycortisol in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (6 beta-hydroxycortisol) | Trials (6 beta-hydroxycortisol) | Recent Studies (post-2010) (6 beta-hydroxycortisol) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 286 | 65 | 51 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreoli, R; Ardizzoni, A; Azzoni, C; Bartolotti, M; Bortesi, B; De Palma, G; Gelsomino, F; Goldoni, M; Mozzoni, P; Mutti, A; Silini, EM; Tiseo, M | 1 |
1 other study(ies) available for erlotinib hydrochloride and 6 beta-hydroxycortisol
| Article | Year |
|---|---|
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Skin; Survival Analysis; Treatment Outcome | 2014 |